# Oblenio Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oblenio-bio

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.obleniobio.com/
- Total disclosed funding: $62M
- Latest round: Series B (Jun 25, 2026)
- Investors on record: 4

## About

Oblenio Bio, Inc., based in the US, is a biotechnology firm that specializes in developing innovative therapies for refractory autoimmune diseases, focusing on advanced and effective solutions for patients.Founded in 2024 and headquartered in Lexington, US, Oblenio Bio, Inc. is dedicated to the advancement of therapies for autoimmune diseases. The company successfully raised USD 62.00 mn in Series B funding on June 25, 2026, led by Pfizer Venture Investments, with participation from Aditum Bio, Deep Track Capital, and GV. This funding targets the clinical development of its key product, LBL-051. As of July 2026, Oblenio Bio is led by Samantha Truex as a CEO. Oblenio Bio specializes in the development of innovative therapies targeting refractory autoimmune diseases, with its core product being the LBL-051 T-cell engager. This tri-specific antibody is engineered to target BCMA, CD19, and CD3, facilitating the safe and effective depletion of pathological B-cells and plasma cells. Designed for patients suffering from severe autoimmune conditions, LBL-051 aims to achieve long-term drug-free remission, offering a potentially groundbreaking approach to treatment. The company is focused on advancing LBL-051's clinical development, with applications across a broad spectrum of autoimmune diseases, including but not limited to rheumatoid arthritis and systemic lupus erythematosus. Oblenio Bio's solutions are intended for the global market, particularly in regions with a high prevalence of autoimmune disorders, such as North America and Europe.Oblenio Bio’s revenue generation strategy primarily revolves around the clinical development and commercialization of its flagship product, LBL-051. The company engages in partnerships with healthcare providers, research institutions, and pharmaceutical companies to facilitate the development and distribution of its therapies. These collaborations involve a combination of licensing agreements and direct sales to hospitals and clinics managing autoimmune disease treatments. Transactions are structured around milestone payments, contingent upon achieving specific development goals, along with royalties on sales post-commercialization. The pricing structure for LBL-051 and related services reflects the advanced nature of the treatment and its anticipated impact on patient outcomes, aligning with industry standards for specialized biopharmaceutical products.In June 2026, Oblenio Bio, Inc. raised USD 62.00 mn in Series B funding led by Pfizer Venture Investments, which will be utilized for the clinical testing of LBL-051 for autoimmune diseases. The company plans to design and launch new products targeting additional autoimmune conditions, expanding its market reach into North America and Europe by 2028.

## Funding rounds

- Series B, Jun 25, 2026, $62M — GV, Pfizer Venture Investments, Deep Track Capital, Aditum Bio

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- Aditum Bio (https://capitalatlas.ai/funds/aditum-bio) — Series B